Entrada Therapeutics (TRDA) EBT (2020 - 2026)
Entrada Therapeutics' quarterly EBT came in at -$39.7 million in Q1 2026, down 128.71% year-on-year from $138.2 million in Q1 2025, and down 1.55% quarter-over-quarter from -$39.1 million in Q4 2025.
Entrada Therapeutics has reported EBT for 7 years, with the latest figure at -$39.7 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 128.71% year-over-year to -$39.7 million; the trailing twelve-month figure through Mar 2026 stood at -$165.2 million (down 793.67% YoY), and the FY2025 full-year result was -$142.8 million, down 314.82% from the prior year.
- EBT for Q1 2026 stood at -$39.7 million, down from -$39.1 million in the prior quarter.
- The five-year high for EBT was $57.8 million in Q2 2024, with the low at -$43.5 million in Q3 2025.
- Average EBT over 5 years is -$11.7 million, with a median of -$17.3 million recorded in 2025.
- Year-over-year, EBT soared 910.98% in 2024 and slumped 5187.14% in 2025.
- Tracing TRDA's EBT over 5 years: stood at -$24.6 million in 2022, then jumped by 137.52% to $9.2 million in 2023, then tumbled by 108.0% to -$739000.0 in 2024, then sank by 5187.14% to -$39.1 million in 2025, then decreased by 1.55% to -$39.7 million in 2026.
- The last three EBT figures came in at -$39.7 million (Q1 2026), -$39.1 million (Q4 2025), and -$43.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Entrada Therapeutics | 295.78 Mn | 295.78 Mn | - | -39.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.68 Mn |
| Dec 31, 2025 | -39.07 Mn |
| Sep 30, 2025 | -43.48 Mn |
| Jun 30, 2025 | -42.93 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | -739,000.00 |
| Sep 30, 2024 | -15.89 Mn |
| Jun 30, 2024 | 57.79 Mn |
| Mar 31, 2024 | 25.33 Mn |
| Dec 31, 2023 | 9.24 Mn |
| Sep 30, 2023 | 18.06 Mn |
| Jun 30, 2023 | -12.08 Mn |
| Mar 31, 2023 | -3.12 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -18.45 Mn |
| Sep 30, 2021 | -14.43 Mn |
| Jun 30, 2021 | -9.90 Mn |
| Mar 31, 2021 | -8.38 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -6.99 Mn |